Drug developer ImmuPharma PLC (AIM:IMM) (LON:IMM; Euronext Growth Brussels:ALIMM) announced a number of boardroom changes including the departure of its long-serving chief executive to “pursue a number of other external opportunities”.
After 16 years with the company, Dimitri Dimitriou is handing over the reins to Tim McCarthy with the search now underway to identify the latter’s successor as chairman.
In the same announcement, ImmuPharma said it appointed Dr Sanjeev Pandya as senior independent director and Lisa Baderoon as a non-executive director after Dr Franco di Muzio and Dr Stéphane Méry “decided that now is an appropriate time for each of them to step down from the board”.
Pandya, formerly CEO of Advanced Oncotherapy, has raised over US$100mln and developed and secured partnerships in the US, EU, China, Singapore, India, Australia, Asia and South America. Baderoon has been advising ImmuPharma since its flotation on AIM in 2006 and was appointed head of investor relations in 2012.
McCarthy said: "We would like to take this opportunity to thank Dimitri, Franco and Stéphane for their hard work during their time in the business.
“In particular, having co-founded ImmuPharma in 2005, Dimitri has put in a considerable tenure as CEO with the various successes and challenges faced by the business over the years.”
The company’s lead asset is a phase III treatment for lupus called Lupuzor, which is being developed in partnership with Avion Pharmaceuticals.